SC
RYTM icon

Stempoint Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Stempoint Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,915
Closed -$6.31M – 112
2025
Q4 		$6.31M Sell
58,915
-32,529
-36% -$3.45M 1.08% 31
2025
Q3 		$9.23M Sell
91,444
-85,308
-48% -$7.92M 1.85% 13
2025
Q2 		$11.2M Buy
176,752
+142,936
+423% +$8.75M 3.58% 9
2025
Q1 		$1.79M Sell
33,816
-174,200
-84% -$9.66M 0.57% 38
2024
Q4 		$11.6M Buy
208,016
+166,748
+404% +$9.21M 2.91% 10
2024
Q3 		$2.16M Buy
+41,268
New +$1.98M 0.65% 37

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Stempoint Capital's RYTM Position: Q1 2026 in Review

Stempoint Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 58,915 shares — an estimated $6.31M sold.

Stempoint Capital first reported a position in RYTM in Q3 2024 and held it in 6 quarters. The position peaked at $11.6M in Q4 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Stempoint Capital reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 58,915 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $6.31M.
  • Stempoint Capital first reported a position in Rhythm Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Stempoint Capital's Rhythm Pharmaceuticals position peaked at $11.6M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.